Guangchun He Selected Research

Lovastatin (Mevacor)

1/2022	Lovastatin enhances chemosensitivity of paclitaxel-resistant prostate cancer cells through inhibition of CYP2C8.
1/2021	Lovastatin Inhibits EMT and Metastasis of Triple-Negative Breast Cancer Stem Cells Through Dysregulation of Cytoskeleton-Associated Proteins.
1/2020	Reversal of HER2 Negativity: An Unexpected Role for Lovastatin in Triple-Negative Breast Cancer Stem Cells.
2/2018	Cerasomal Lovastatin Nanohybrids for Efficient Inhibition of Triple-Negative Breast Cancer Stem Cells To Improve Therapeutic Efficacy.
1/2018	Nucleolar stress: is there a reverse version?
1/2017	Lovastatin Inhibits Cancer Stem Cells and Sensitizes to Chemo- and Photodynamic Therapy in Nasopharyngeal Carcinoma.
1/2016	Effects of Lovastatin on MDA-MB-231 Breast Cancer Cells: An Antibody Microarray Analysis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Guangchun He Research Topics

Disease

11	Neoplasms (Cancer) 01/2022 - 01/2008
7	Breast Neoplasms (Breast Cancer) 01/2022 - 01/2016
6	Neoplasm Metastasis (Metastasis) 01/2021 - 01/2007
5	Triple Negative Breast Neoplasms 01/2022 - 01/2017
3	Prostatic Neoplasms (Prostate Cancer) 01/2022 - 01/2008
1	Hyperlipidemias (Hyperlipidemia) 01/2022
1	Colorectal Neoplasms (Colorectal Cancer) 03/2021
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021
1	Lymphatic Metastasis 08/2019
1	Hypercholesterolemia 01/2017
1	Nasopharyngeal Carcinoma 01/2017
1	Hepatocellular Carcinoma (Hepatoma) 01/2015
1	Carcinogenesis 01/2015
1	Bone Resorption 07/2014
1	Lung Neoplasms (Lung Cancer) 01/2007

Drug/Important Bio-Agent (IBA)

7	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2008
7	Lovastatin (Mevacor)FDA LinkGeneric 01/2022 - 01/2016
2	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2021 - 01/2018
2	Biomarkers (Surrogate Marker)IBA 08/2019 - 01/2017
2	Parathyroid Hormone-Related ProteinIBA 01/2015 - 01/2007
1	PhosphoproteinsIBA 01/2022
1	Cytochrome P-450 CYP2C8IBA 01/2022
1	Paclitaxel (Taxol)FDA LinkGeneric 01/2022
1	Pharmaceutical PreparationsIBA 01/2022
1	Hormones (Hormone)IBA 01/2022
1	Hydroxymethylglutaryl CoA Reductases (HMG CoA Reductase)IBA 01/2022
1	Photosensitizing Agents (Photosensitizers)IBA 03/2021
1	pyropheophorbide aIBA 03/2021
1	Peptides (Polypeptides)IBA 03/2021
1	1-phenyl-3,3-dimethyltriazene (PDT)IBA 03/2021
1	artemisinin (artemisinine)IBA 01/2021
1	Antimalarials (Antimalarial Agents)IBA 01/2021
1	ArtesunateIBA 01/2021
1	artenimol (dihydroartemisinin)IBA 01/2021
1	Crystallins (Crystallin)IBA 08/2019
1	Epithelial Cell Adhesion MoleculeIBA 08/2019
1	Progesterone Receptors (Progesterone Receptor)IBA 01/2017
1	human ERBB2 proteinIBA 01/2017
1	Estrogen ReceptorsIBA 01/2017
1	AnthracyclinesIBA 01/2017
1	Taxoids (Taxanes)IBA 01/2017
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2017
1	UbiquitinIBA 01/2015
1	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2015
1	Proteasome Endopeptidase Complex (Proteasome)IBA 01/2015
1	Cytostatic AgentsIBA 01/2015
1	Matrix Metalloproteinases (MMPs)IBA 01/2008
1	Tissue Inhibitor of Metalloproteinase-1IBA 01/2008
1	CalciumIBA 01/2008
1	Peptide Hydrolases (Proteases)FDA Link 01/2008
1	GelatinIBA 01/2008
1	Tissue Inhibitor of Metalloproteinase-2IBA 01/2008
1	Protein Isoforms (Isoforms)IBA 01/2007
1	ezrinIBA 01/2007
1	RNA IsoformsIBA 01/2007
1	Messenger RNA (mRNA)IBA 01/2007

Therapy/Procedure

6	Therapeutics 01/2022 - 07/2014
2	Photochemotherapy (Photodynamic Therapy) 03/2021 - 01/2017
1	Drug Therapy (Chemotherapy) 01/2022
1	Intravenous Injections 02/2018
1	Molecular Targeted Therapy 07/2014
1	Castration 07/2014